Consistent with previous findings in lymphoma [42] and colorectal cancer [43], we showed that individual add-back with mevalonate, FPP and GGPP was able to reverse simvastatin-induced apoptosis, proliferation inhibition and deactivation of PI3K/Akt and MAPK/ERK signalling in breast cancer cell lines. Here, AKT1 is linked to lymphoma.